Yonago Acta Medica
Online ISSN : 1346-8049
ISSN-L : 0513-5710
Original Article
Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer
Yusuke KimuraMasashi HondaShuichi MorizaneKatsuya HikitaTadahiro IsoyamaKoji OnoTsutomu KoumiChihiro TakahashiAtsushi Takenaka
Author information

2019 Volume 62 Issue 2 Pages 191-197


Background To evaluate the efficacy of Bacilli Calmette-Guerin (BCG) induction instillation therapy after second transurethral resection (TUR) in stage Ta T1 high-grade bladder cancer.

Methods We performed a retrospective analysis of 49 consecutive new onset Ta T1 high-grade bladder cancer patients treated with second TUR at our affiliated institutions. Residual cancer rate, intravesical recurrence-free survival (RFS), and risk factors related to RFS were evaluated by univariate and multivariate Cox proportional hazard model analyses.

Results Thirty-one patients received BCG therapy after the second TUR (BCG group), and 18 patients were treated with second TUR alone (no BCG group). There were statistically significant differences in the RFS rates between the two groups, (P = 0.037). BCG therapy was the only factor predictive of intravesical recurrence after second TUR in both univariate and multivariate analyses. After the second TUR, BCG therapy significantly decreased intravesical recurrence in the patients with residual tumors (P = 0.014). However, there was no significant difference in intravesical recurrence in the patients with no residual tumors between the two groups (P = 0.359).

Conclusion BCG therapy after second TUR significantly decreased intravesical recurrence of residual tumors found at the second TUR.

Content from these authors
© 2019 Tottori University Faculty of Medicine
Previous article Next article